EMA Withdrawn: Kepivance (palifermin) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

EMA withdrew Kepivance (palifermin) from its approved use for mucositis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucositis

Drugs mentioned

• Kepivance (Palifermin)

Snippet

Status: Withdrawn. Therapeutic area: Mucositis. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 01/04/2016